We understand that businesses within life science face a rapidly evolving landscape with frequently changing regulatory requirements and a range of emerging risks.

— INDUSTRY

Life Sciences

Managing risk to protect your innovations

Contact us

Flexible approach, local knowledge, and a global reach

We understand that businesses within life science face a rapidly evolving landscape with frequently changing regulatory requirements and a range of emerging risks.

We have an intense focus on client service and a real passion to challenge and explore every aspect of risk associated with your business. This gives you the assurance of having a program that is tailored to your unique requirements.

In a changing insurance market, as specialists, we challenge our clients with fresh thinking and work with them to develop quality risk profiles to present to underwriters for optimum outcomes.

Being the world’s largest privately-owned insurance broker, our clients benefit from the strong relationships Lockton has built with domestic and international providers.

Our own Global Healthcare Network, gives us powerful leverage within the marketplace to successfully deliver cost-effective, bespoke insurance programs for each client’s individual requirements; without jeopardising coverage.

A creative and expanding range of solutions

We understand that the life sciences industry is different and a customised program is crucial in protecting businesses involved in pharmaceutical, research and development, medical device manufacturing, and human clinical trials. When it comes to managing risk it’s the quality of our thinking and our proactive approach that makes us different.

We also recognise the executive risk challenges faced by boards across the spectrum of life sciences and pharmaceutical companies, particularly those listed on the ASX. Whether it be renewal of your D&O liability insurance, coverage for a forthcoming initial public offering or new capital raising, we will work closely with you to ensure your program reflects your own risk appetite at a competitive premium.

Lockton is a member of AusBiotech, the leading Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy.

Products and Services

By understanding what you do and what your individual needs are, we ensure there are no coverage gaps or overlaps within your insurance program including:

  • Life Science Insurance 

  • Clinical Trials Insurance, along with the ability to deliver quick issuance of certification

  • Product Liability

  • Property and Business Interruption, including supply chain risk

  • Professional Indemnity 

  • Directors & Officers

  • Cyber

  • Other specialised life sciences services, such as:

    • product recall;

    • medical malpractice;

    • supply chain risk review;

    • marine cargo;

    • employee benefits; and

    • additional industry solutions.

An industry-leading team of experts focused on the unique risks facing the life sciences industry.

Download our brochure

Life Sciences

Lockton Life Sciences Brochure
PDF2484 KB

Key Contacts

Placeholder image

Robert Giardina

Manager - Global Professional & Financial Risks
robert.giardina@lockton.com
+61 455 129 332

General Inquiries

Get in touch

info.au@lockton.com

We're here to help

We bring creative thinking and an entrepreneurial spirit to the insurance business and are uniquely positioned to help you succeed.

Talk to our team

Latest news and insights

Presenteeism: Friend of the “quiet quitter” but a costly foe to organisations

article
Snapshot: Beyond sick days: we explain and identify presenteeism’s causes and effects, and how organisations can overcome it. The link between presenteeism and the “quiet quitter” which is leading to more frequent/longer absences and staff turnover. The insura ...
Read morePresenteeism: Friend of the “quiet quitter” but a costly foe to organisations

The impact of interest rates and inflation on credit and political risks

As the global economy continues to feel the effect of the global pandemic and the ongoing war in Ukraine, world economies are now also facing a need to balance interest rates with rising inflation. Leading economists and central banks must deliberate on how best to manage these issues, and the secondary effects they bring with them, such as energy shortages and an increased cost of living. At the same time, businesses will continue to face market volatility and pressure on their supply chains. As the global economy continues to feel the effect of the global pandemic and the ongoing war in Ukraine, world economies are now also facing a need to balance interest rates with rising inflation. Leading economists and central banks must deliberate on how best to manage these issues, and the secondary effects they bring with them, such as energy shortages and an increased cost of living. At the same time, businesses will continue to face market volatility and pressure on their supply chains.

Tech layoffs: Q&A with Morag Fitzsimons

The economic climate has led to redundancies across the technology sector as companies reduce their costs to try to extend their runways. One of the unintended consequences of this is the impact on workers’ compensation which drives business costs up even further. The economic climate has led to redundancies across the technology sector as companies reduce their costs to try to extend their runways. One of the unintended consequences of this is the impact on workers’ compensation which drives business costs up even further.

Boardroom Briefing - September 2022

With the increasing spotlight and expectations on companies around environmental, social and governance issues come new and evolving areas of risk for boards and insurers. Listed companies, super funds and managed funds are firmly in ASIC’s sights for potential “greenwashing”. This emerging area of risk will continue to develop. With the increasing spotlight and expectations on companies around environmental, social and governance issues come new and evolving areas of risk for boards and insurers. Listed companies, super funds and managed funds are firmly in ASIC’s sights for potential “greenwashing”. This emerging area of risk will continue to develop.
See all news and insights

With a global footprint of over 100 offices, there’s sure to be one near you.

Find an office
*100+ Lockton offices and partner offices worldwide
Lockton blue globe